Scientific program
Session Key:
| Pre-Congress Workshop |
Plenary Session |
Parallel Session |
Free Papers Session |
Industry Symposium |
Thursday, October 8, 2026
| 09:30-12:30 |
Pre-Congress Workshop 1:
Breast imaging masterclass: Limitations and pitfalls of common breast imaging tools |
Hall A
(Great Hall 1) |
| Chairpersons |
|
| 09:30-11:00 |
|
| 11:00-11:20 |
Coffee Break |
| 11:20-12:30 |
|
| 09:30-12:30 |
Pre-Congress Workshop 2:
The expanding role of genetic testing in breast cancer: Therapeutic, surgical and surveillance implications
|
Hall B
(Great Hall 2) |
| Chairperson |
|
| 09:30-11:00 |
|
| 11:00-11:20 |
Coffee Break |
| 11:20-12:30 |
|
| 09:30-12:30 |
Pre-Congress Workshop 3:
Treating the extremes
|
Hall C
(Room M1) |
| Chairperson |
|
| 09:30-11:00 |
|
| 11:00-11:20 |
Coffee Break |
| 11:20-12:30 |
|
| 09:30-12:30 |
Pre-Congress Workshop 4:
Communication workshop: How to improve a patient’s understanding of risk, prognosis, treatment choices and expectations
|
Hall D
(Room F1) |
| Chairperson |
|
| 09:30-11:00 |
|
| 11:00-11:20 |
Coffee Break |
| 11:20-12:30 |
|
| 14:00-15:00 |
Industry Symposium
|
Hall C
(Room M1) |
| Chairperson |
|
|
|
| 15:00-15:15 |
Congress Opening |
Hall A
(Great Hall 1) |
| Chairpersons: |
Bruce Mann, Melbourne, Australia
Caroline Baker, Melbourne, Australia
Peter Chin, Tauranga, New Zealand
|
|
Welcome to Country |
|
Welcome from Congress chairpersons |
| 15:15-17:00 |
Plenary Session 1:
Neoadjuvant therapy |
Hall A
(Great Hall 1) |
| Chairpersons |
|
15:15-15:55
15:15
15:30
15:45 |
Debate: That cT1cN0 TNBC should have Neoadj CT and IO
Yes:
No:
Discussion |
| 15:55-16:15 |
Didactic: How best to monitor a patient during neoadjuvant therapy |
16:15-17:00
16:15
16:30
16:45
16:55 |
Debate: That patients with pN+ luminal cancer who are ypN0 after NAST should receive regional nodal radiotherapy
Yes:
No:
Discussion
Consumer perspective |
| 17:00-18:00 |
Networking Reception (in exhibition area) |
Friday, October 9, 2026
| 07:30-08:30 |
Morning Industry Symposium:
Supported by Veracyte
Please note breakfast will be served prior to the session. at 07:00 |
Hall B
(Great Hall 2) |
| 07:30-08:30 |
Morning Industry Symposium:
Supported by MSD
Please note breakfast will be served prior to the session. at 07:00 |
Hall C
(Room M1) |
| 08:30-09:30 |
Parallel Session 2:
Screening |
Hall A
(Great Hall 1) |
| Chairpersons |
|
| 08:30-08:55 |
Didactic: Risk adjusted screening – what might it look like? |
| 08:55-09:10 |
Didactic: The future of post-breast cancer surveillance |
| 09:10-09:30 |
Didactic: Artificial intelligence in breast cancer screening |
| 08:30-09:30 |
Parallel Session 3:
Fear of cancer recurrence |
Hall B
(Great Hall 2) |
| Chairpersons |
|
| 08:30-08:50 |
Fear of cancer recurrence: What is it, and how common is it? |
| 08:50-09:10 |
Is it possible to conquer fear of recurrence?
Fear of cancer recurrence in First Nations women |
| 09:10-09:30 |
Consumer representative |
| 08:30-09:30 |
Industry Symposium:
Supported by Lilly
|
Hall C
(Room M1) |
| 09:30-11:00 |
Plenary Session 4:
Genetics |
Hall A
(Great Hall 1) |
| Chairpersons |
|
| 09:30-09:50 |
Didactic: Panel testing in early breast cancer: Who, when and why? |
| 09:50-10:30
09:50
10:05
10:20 |
Debate: That Breast-Conserving Surgery is an appropriate recommendation for most patients with high-penetrance germline mutations
Yes:
No:
Discussion |
| 10:30-10:50 |
Didactic: Management of ovaries/fallopian tubes in gene carriers – what to do and when to do it? |
| 10:50-11:00 |
Consumer perspective |
| 11:00-11:30 |
Coffee break, poster viewing and exhibition visit |
| 11:30-12:30 |
Parallel Session 5:
Lymphoedema |
Hall A
(Great Hall 1) |
| Chairpersons |
|
| 11:30-11:50 |
What is the evidence behind advice regarding lymphoedema prevention? |
| 11:50-12:10 |
Evidence based treatment modalities for established lymphoedema: What works? What doesn’t? |
| 12:10-12:30 |
Surgery for lymphoedema: Prevention and treatment |
| 11:30-12:30 |
Industry Symposium:
Supported by AstraZeneca
|
Hall B
(Great Hall 2) |
| 11:30-12:30 |
Parallel Session 6:
Free Papers: Locoregional therapy |
Hall C
(Room M1) |
| Chairpersons |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 12:30-13:30 |
Lunch break, poster viewing and exhibition visit |
| 13:30-14:30 |
Parallel Session 7:
DCIS |
Hall A
(Great Hall 1) |
| Chairpersons |
|
13:30-14:00
13:30
13:40
13:50 |
Debate: That genomic assays should be used to help make decisions regarding adjuvant RT for DCIS
Yes:
No:
Discussion |
14:00-14:30
14:00
14:10
14:20 |
Debate: That active surveillance for low risk DCIS is a reasonable option
Yes:
No:
Discussion |
| 13:30-14:30 |
Parallel Session 8:
Triple negative breast cancer
|
Hall B
(Great Hall 2) |
| Chairpersons |
|
| 13:30-13:45 |
TNBC subtypes: Do they have clinical significance? |
13:45-14:30
13:45
14:00
14:15 |
Debate: That all stage 2/3 TNBC patients should be treated according to Keynote522 regimen
Yes:
No:
Discussion |
| 13:30-14:30 |
Parallel Session 9:
Free Papers: Supportive care |
Hall C
(Room M1) |
| Chairpersons |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 14:30-15:50 |
Plenary Session 10:
Adjuvant endocrine therapy |
Hall A
(Great Hall 1) |
| Chairpersons |
|
14:30-15:10
14:30
14:45
15:00 |
Debate: That CDK4/6i’s should be recommended for T2N0 ER+HER2- early breast cancer
Yes:
No:
Discussion |
| 15:10-15:35 |
Didactic: Oral SERDS in early breast cancer: where to now? |
| 15:35-15:50 |
Didactic: Modern management of hot flushes in breast cancer patients |
| 15:50-16:10 |
Coffee break, poster viewing and exhibition visit |
| 16:10-17:15 |
Parallel Session 11:
Imaging |
Hall A
(Great Hall 1) |
| Chairpersons |
|
| 16:10-16:50
16:10
16:25
16:40 |
Debate: That Contrast Breast Imaging should be routine prior to surgery for DCIS or invasive cancer, even for those with mammographic density A or B
Yes:
No:
Discussion |
| 16:55-17:15 |
Didactic: How to select which contrast imaging to use |
| 16:10-17:15 |
Parallel Session 12:
Metastatic breast cancer |
Hall B
(Great Hall 2) |
| Chairpersons |
|
16:10-16:55
16:10
16:25
16:40 |
Debate: That SABR should be considered in most patients with oligometastatic breast cancer
Yes:
No:
Discussion |
| 16:55-17:15 |
Didactic: The role of molecular testing to adapt breast cancer treatment in clinical practice |
| 16:10-17:15 |
Parallel Session 13:
Supportive care: Management of endocrine therapy side effects |
Hall C
(Room M1) |
| Chairpersons |
|
| 16:10-16:30 |
Alopecia |
| 16:30-16:50 |
Sleep and health related QoL |
| 16:50-17:10 |
Arthralgia and mylagias |
| 17:10-17:15 |
Discussion |
Saturday, October 10, 2026
| 07:30-08:30 |
Morning Industry Symposium:
Supported by Novartis
Please note breakfast will be served prior to the session. |
Hall B
(Great Hall 2) |
| 07:30-08:30 |
Morning Industry Symposium:
Supported by TBA
Please note breakfast will be served prior to the session. |
Hall C
(Room M1) |
| 08:30-09:30 |
Parallel Session 14:
Controversies in reconstruction |
Hall A
(Great Hall 1) |
| Chairpersons |
|
| 08:30-08:45 |
Didactic: Scaffolds in reconstruction – past, present and future |
08:45-09:15
08:45
08:55
09:05 |
Debate: That implant reconstruction should not be performed on patients who require PMRT
Yes:
No:
Discussion |
| 09:15-09:30 |
Didactic: Consumer voice informing the future of breast reconstruction in Australia |
| 08:30-09:30 |
Parallel Session 15:
Survivorship |
Hall B
(Great Hall 2) |
| Chairpersons |
|
| 08:30-08:45 |
What matters most to consumers?
|
| 08:45-09:00 |
Survivorship MoC based around nurse led clinics |
| 09:00-09:15 |
McGrath model of survivorship care |
| 09:15-09:30 |
Living well with metastatic disease/fear of cancer progression |
| 08:30-09:30 |
Parallel Session 16:
Free Papers: Medical oncology |
Hall C
(Room M1) |
| Chairpersons |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 09:30-11:00 |
Plenary Session 17:
Locoregional therapy |
Hall A
(Great Hall 1) |
| Chairpersons |
|
09:30-10:10
09:30
09:45
10:00 |
Debate: That omission of SNB should be considered for all women >50 with clinically negative axillae
Yes:
No:
Discussion |
| 10:10-10:30 |
Didactic: Axillary surgery post-neoadjuvant therapy |
10:30-11:00
10:30
10:40
10:50 |
Debate: That most patients with Stage 2+ early breast cancer should have staging PET/CT
Yes:
No:
Discussion |
| 11:00-11:30 |
Coffee break, poster viewing and exhibition visit |
| 11:30-13:00 |
Parallel Session 18:
Local therapy |
Hall A
(Great Hall 1) |
| Chairpersons |
|
11:30-12:00
11:30
11:40
11:50 |
Debate: New intraoperative margin assessment technology will become standard of care
Yes:
No:
Discussion |
12:00-12:30
12:00
12:15 |
The future of breast surgery
European perspective:
North American perspective:
|
| 11:30-13:00 |
Parallel Session 19:
HER2 positive disease |
Hall B
(Great Hall 2) |
| Chairpersons |
|
| 11:30-11:50 |
Didactic: Role of endocrine therapy in advanced TPBC |
11:50-12:40
11:50
12:05
12:20 |
Debate: That T-DXd should be included in the neo-adjuvant treatment for higher risk Her2 positive patients
Yes:
No:
Discussion |
| 12:40-13:00 |
Didactic: Is chemotherapy still necessary in early-stage HER2+ve breast cancer? |
| 13:00-14:00 |
Lunch break, poster viewing and exhibition visit |
| 13:10-13:55 |
Lunch Industry Symposium:
Supported by Hologic
|
Hall B
(Great Hall 2) |
| 14:00-15:00 |
Plenary Session 20:
Palliative care |
Hall A
(Great Hall 1) |
| Chairpersons |
|
14:00-14:30
14:00
14:10
14:20 |
Debate: Is palliative care involvement necessary from initial diagnosis of metastatic disease
Yes:
No:
Discussion |
| 14:30-15:00 |
Medicinal cannabis in advanced cancer: Pot or panacea? |
| 15:00-16:15 |
Plenary Session 21:
Breast cancer 2036 |
Hall A
(Great Hall 1) |
| Chairpersons |
|
| 15:00-15:15 |
Early detection in 2036 |
| 15:15-15:30 |
A pathologist’s view of breast cancer in 2036 |
| 15:30-15:45 |
Systemic therapy in 2036 |
| 15:45-16:00 |
Locoregional therapy in 2036 |
| 16:00-16:15 |
A consumer’s perspective of breast cancer in 2036 |
| 16:15-16:30 |
Congress closing
and Award presentation
|
Hall A
(Great Hall 1) |
| Chairpersons |
Bruce Mann, Melbourne, Australia
Caroline Baker, Melbourne, Australia
Peter Chin, Tauranga, New Zealand |
